MLN3897
MLN3897 is an orally active CCR1 antagonist. MLN3897 inhibits the c-fos and Akt pathways by blocking the binding of CCL3 to CCR1, thereby reducing immune cell infiltration, attenuating osteoclasts, and interfering with tumor-microenvironment interactions. MLN3897 can be used in research on multiple myeloma, multiple myeloma bone disease, and rheumatoid arthritis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 690660-17-4
- 分子式: C30H31ClN2O4
- 分子量:519.03
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
AP-1 アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
|
CCR1 |
c-Fos |
Akt |
体外実験
MLN3897 impairs osteoclast formation and function in multiple myeloma by reducing precursor cell multinucleation and downregulating c-fos signaling; by inhibiting the Akt signaling pathway, it blocks CCL-3 (HY-P7256)-induced multiple myeloma cell migration and can inhibit the adhesion of multiple myeloma cells to osteoclasts[3].
MLN3897 inhibits CCR1-mediated internalization of Alexa647-CCL3 in human whole blood with an IC50 of 45 nM[2].
MLN3897 potently inhibits CCL15 (HY-P7266)-induced chemotaxis of freshly isolated human monocytes in 100% human serum, with an IC50 of 2 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID (humanized model, SCID-hu)[1]
-
Dosage:2 mg/kg
-
Administration:p.o.; once daily; 4 weeks
-
Result:Decreased shIL6R levels in treated mice.
Reduced tumor infiltration to 26% versus 40% in vehicle controls.
Decreased osteoclast number per bone area to 29 versus 46.2 in controls.
Increased trabecular area/bone area (TA/BA) to 27 versus 15.9 in controls.
Observed osteoblast number per mm2 bone of 506 versus 575 in controls.
Increased osteocalcin-positive area/trabecular area (OCN+/TA) to 0.53 versus 0.26 in controls.
化学情報
-
CAS 番号 690660-17-4
-
分子量 519.03
-
分子式 C30H31ClN2O4
-
SMILES
CC(C)([C@](CC1)(C2=CC=C(C=C2)Cl)O)CN1CC/C=C3C4=CC(C(O)=O)=CC=C4OCC5=NC=CC=C5/3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Vallet S, et al. CCR1 as a target for multiple myeloma. Expert opinion on therapeutic targets. 2011 Sep;15(9):1037-47. [Content Brief]
[2]. Dairaghi DJ, et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clinical pharmacology and therapeutics. 2011 May;89(5):726-34. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MLN3897 関連分類
HY-15544A 関連分類
Powered by Bioz